Artiva Biotherapeutics, Inc.ARTVNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank9
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P9
Near historical low
vs 2Y Ago
-0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-6.19%
Q3 20256.36%
Q2 2025-3.32%
Q1 20253.41%
Q4 20242.89%
Q3 202424.73%
Q2 20247.53%
Q1 202413.26%
Q4 202313.92%
Q3 2023-31.51%
Q2 20233.92%
Q1 20230.00%